QIAGEN COVID-19 emergency protocols

COVID-19 | Updated Regularly

Global efforts in the fight against coronavirus

From the onset of the novel coronavirus outbreak, QIAGEN’s dedicated global teams have been working around the clock to ensure the availability of existing testing solutions and to develop new SARS-CoV-2 tests to address international testing needs. We have dramatically scaled up production, moving to 24 hour, seven-day-a-week operations at our manufacturing sites, and are investing in additional equipment capacity. Today, we offer the most comprehensive portfolio of SARS-CoV-2 testing solutions on the market, covering the needs of clinical and research customers, from manual to automated sample processing, low to high throughput, single-plex to multi-plex, and from active infection testing to the detection of previous viral exposure.

Background information on QIAGEN solutions, the coronavirus, and how coronavirus testing works available here (Updated November 20th).


Samples of QIAGEN in the Media

Supporting healthcare workers around the world in the fight against COVID-19

QIAGEN supports several testing protocols by providing test components, mid- to high-throughput automation solutions, and a multiplex syndromic detection solution. We also support scientists seeking to better understand the SARS-CoV-2 virus with research tools, including sequencing components and tools for data analysis and interpretation. We will continue to work tirelessly on novel approaches.

QIAGEN support in current testing protocols for emergency use

Product availability varies by country. Please contact your country representative or complete the support request form for further details. Please also review the protocols themselves for alternative solutions from other suppliers.

RNA extraction

Given the current public health emergency with COVID-19, QIAGEN and other companies are facing unprecedented demand for viral RNA isolation solutions. QIAGEN has developed dedicated solutions for viral RNA isolation that have been optimized for maximum sensitivity and reproducibility. We recognize that currently, scientists are seeking to use various QIAGEN kits, such as RNeasy, for SARS-CoV-2 RNA isolation from respiratory samples. It is critical to note that these kits have not been designed for isolating viral RNA, and performance of each kit varies. The user must consult the product-specific handbook or user manual. We strongly recommend using only dedicated RNA isolation products for SARS-CoV-2, such as those listed below:

Solutions authorized for use for COVID-19 testing in some regions (please check local regulations)
Research solutions

Antigen testing

QIAreach SARS-CoV-2 Antigen Test

The QIAreach SARS-CoV-2 Antigen Test is a scalable, digital assay for the in vitro detection of the SARS-CoV-2 nucleocapsid protein antigen. It lets you test up to eight patients at once for SARS-CoV-2 infection – with first positive results in just two minutes. As part of the complete QIAreach Solution, you can run the QIAreach SARS-CoV-2 Antigen Test together with the QIAreach SARS-CoV-2 Total antibody test on a single QIAreach eHub.


Antibody testing

QIAreach Anti-SARS-CoV-2 Total Test

To enable accessible and accurate SARS-CoV-2 antibody testing, QIAGEN now offers the QIAreach Anti-SARS-CoV-2 Total Test (Anti-CoV2). The Anti-CoV2 test enables rapid, qualitative detection of total antibodies to SARS-CoV-2. Features include Total Ig detection (IgA, IgM, and IgG), results in approximately 10 minutes, and the ability to test up to 8 patients simultaneously on the digital QIAreach eHub. 

Syndromic Testing

QIAGEN multiplex syndromic testing support for SARS-CoV-2*

To support the efforts for accessible testing to meet the demands of the COVID-19 outbreak, QIAGEN has developed the QIAstat-Dx Respiratory SARS-CoV-2 Panel. This version of our multiplex syndromic cartridge enables detection of the SARS-CoV-2 virus that causes COVID-19 in addition to 20+ other respiratory pathogens.*

Targeted PCR Testing

NeuMoDx Systems
The NeuMoDx 96 and NeuMoDx 288 systems offer a rapid and fully automated PCR test for the detection of SARS-CoV-2, under FDA Emergency Use Authorization, that can deliver a result within an hour. A new multiplex test for influenza, respiratory syncytial virus (RSV) and the SARS-CoV-2 virus is scheduled for launch in the fourth quarter of this year. NeuMoDx systems provide an ideal solution for hospitals or central testing labs, delivering the speed and flexibility to support the large numbers of patient samples they receive. 
NeuMoDx 96 and NeuMoDx 288 Systems.

Tailored oligonucleotides for SARS-CoV-2 detection

Updated April 27

In our effort to support the detection of the SARS-CoV-2 virus, OEM by QIAGEN has ramped up the production of SARS-CoV-2 specific primers and probes. We provide customized oligos defined by our customers, as well as those mentioned in protocols recommended by WHO and the CDC. To meet the high demands, we are currently prioritizing the orders of SARS-CoV-2 specific oligonucleotides. In addition, we have introduced pre-manufacturing of these oligonucleotides to enable quick supply and delivery. To order, please send your requests here.
Learn more about OEM by QIAGEN.

Innovative PCR solution for coronavirus molecular epidemiology research

The novel and innovative QIAprep&amp Viral RNA UM Kit combines a liquid-based sample preparation step completed in only two minutes with RT-qPCR detection in a streamlined workflow that takes under one hour to deliver results for SARS-CoV-2 coronavirus epidemiological research. With a simple three-step workflow, compatibility with the most common transport media such as UTM™ as the starting material, and the possibility to automate with standard lab equipment for any throughput, any assay and single to multiplex testing, this kit can significantly accelerate the turnaround time and the frequency of viral testing – compared to approximately three hours for standard extraction-based qPCR approach. The kit is optimized for reliable and sensitive processing of up to 2600 samples per eight-hour shift per cycler. 


NGS resources for coronavirus molecular epidemiology, vaccine development and drug discovery research

The new QIAseq SARS-CoV-2 Primer Panel enables targeted enrichment and deep sequencing of the complete SARS-CoV-2 genome. With a single-day workflow, and the ability to multiplex up to 384 samples when combined with the QIAseq FX DNA Library UDI Kit, this NGS panel provides faster results – with lower input requirements – compared with hybrid capture approaches. Rapid sequence and phylogenetic data analysis are also available using pre-built and optimized pipelines in the QIAGEN CLC Genomics Workbench. Obtain a trial kit of the QIAseq SARS-CoV-2 Primer Panel and learn more about the complete solution here.


Whole Genome Sequencing Services

QIAGEN Genomic Services provides a comprehensive Sample-to-Insight SARS-CoV-2 Whole Genome Sequencing Services to support your research. Whether you’re studying strain evolution or performing phylogeographic or metagenomic analyses, Genomic Services is the right partner for providing impactful insights and helping accelerate your COVID-19 research. This service uses technology especially designed for SARS-CoV-2 research.


Bioinformatics analysis of SARS-CoV-2 with QIAGEN Digital Insights

To support the efforts of clinical microbiology and public health laboratories involved in SARS-CoV-2 sequencing, QIAGEN is offering free temporary licenses for QIAGEN CLC Genomics ProSuite. For labs that purchase the QIAseq SARS-CoV-2 Primer Panel Kit (96), we are also offering 25% off subscriptions to QIAGEN CLC Genomics software. Learn more here.

Additionally, our data scientists have expanded upon recent peer-reviewed research to generate relevant SARS-CoV-2 protein networks. This freely available Coronavirus Network Explorer helps you visualize how SARS-CoV-2 proteins interact with human host proteins to disable protective responses and pathways, and explore hypotheses around ways to fight coronavirus.


How can we support your lab?

QIAGEN solutions

*The number of targets/pathogens detected by the QIAstat-Dx Respiratory SARS-CoV-2 Panels is different in different countries.

The QIAstat-Dx Respiratory SARS-CoV-2 Panels are intended for in vitro diagnostic use.

The US version of the QIAstat-Dx Respiratory SARS-CoV-2 Panel is intended for in vitro diagnostic use under Emergency Use Authorization Only. Testing is limited to laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a, to perform high complexity and moderate complexity tests.
The QIAstat-Dx Respiratory SARS-CoV-2 Panel has not been FDA cleared or approved; 
The QIAstat-Dx Respiratory SARS-CoV-2 Panel has been authorized by FDA under an EUA for use by authorized laboratories; 
The QIAstat-Dx Respiratory SARS-CoV-2 Panel has been authorized only for the detection and differentiation of nucleic acid of SARS-CoV-2 from multiple respiratory viral and bacterial organisms; and 
The QIAstat-Dx Respiratory SARS-CoV-2  Panel is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostic tests for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

Cookies help us improve your website experience.
By using our website, you agree to our use of cookies.